Related Experiment Video
Updated: Mar 3, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's
Jean-François Timsit1,2, Marlieke E A de Kraker3, Harriet Sommer4
1UMR 1137 IAME Inserm/Université Paris Diderot, 75018, Paris, France. jean-francois.timsit@bch.aphp.fr.
Purpose:
In this era of rising antimicrobial resistance, slowly refilling antibiotic development pipelines, and an aging population, we need to ensure that randomized clinical trials (RCTs) determine the added benefit of new antibiotic agents effectively and in a valid way, especially for severely ill patients. Unfortunately, universally accepted endpoints for the evaluation of new drugs in severe infections are lacking.
Methods:
We review and discuss the current practices and challenges regarding endpoints in RCTs in this field and propose novel approaches.
Results:
Usual endpoints actually recommended for drug development suffer from important flaws. Mortality requires large sample size and only partly related to the infectious process. Clinical cure rate is highly subjective in critically ill patients where symptoms may be related to other intercurrent events. Currently, composite endpoints, hierarchical nested designs, and competing risks analysis seem to be the most promising new tools for designing and analyzing clinical trials in this area, although they require further validation.
Conclusion:
Regulatory authorities, pharmaceutical companies, and clinicians need to agree on the most appropriate clinical endpoints for severe infections to ensure efficient approval of new, effective antibiotic agents.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Pyelonephritis II: Diagnostic Studies and Management
Antimicrobial Effectiveness
Urine Studies II: Urine Culture and Sensitivity Test
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence